Objective To evaluate whether lipid-lowering therapy with Xuezhikang can reduce the risk of cardiac events and total mortality in aged coronary heart disease(CHD) patients. Methods 2550 aged and 2320 non-aged patients were selected and given with capsule Xuezhikang 0.6 g bid or placebo in addition to conventional therapy.The mean follow-up period was four years. Results The incidence of CHD events and the total mortality of aged patients were significantly higher than the non-aged.The incidence of CHD events was reduced by 41.3% for treatment group(P

Objective To establish the 3rd national standard for un-fractionated heparin for National Institutes for Food and Drug Control(NIFDC).MethodsFour candidate heparin samples(code ampoule 1,2,3,4)were assayed against the International Standard(07/328)and National Standard(150509-200912).Jiangsu Institute for Food and Drug Control(JSIFDC)determined the potency of anti-FXa and anti-FIIa by chromogenic substrate methods and the potency of anticoagulation by whole rabbit blood of Chinese Pharmacopoeia(2015).Results All of the data from our institute were adopted to calculate the 3rd national standard for un-fractionated Heparin.NIFDC analyzed the data from 13 laboratories.The geometric coefficient of variation of inter-laboratory and intra-laboratory were both below 10％.Conclusion Approved by the national drug standards material Committee,the candidate(140817-201501)was recommended to be the 3rd national standard for un-fractionated Heparin with an assigned value of 2011IU per ampoule.

Objective To evaluate the impacts of rosiglitazone and metformin on ovarian response, hirsutism and insulin action in women with polycystic ovary syndrome (PCOS). Methods Ninety women resistant to clomiphene citrate with PCOS were randomized, 40 cases to rosiglitazone group, 50 cases to meformin group. Rosiglitazone and metformon were administered for 6 months in combination with clomiphene citrate on cycle day 5th to 9th, respectively. The clinical evaluations were performed monthly. Reproductive hormone, serum glucose and insulin levels were observed before and after treatment. The data were analyzed using repeated analysis of variance (ANOVA). Results There were significant changes in reducing hirsutism score, serum testosterone level, LH/FSH ratio, and restoration of ovarian ovulation after metformin or rosiglitazone administration respectively (P<0.05). Insulin sensitivity was more significantly improved in the rosiglitazone group than in metformin group (P<0.05) After treatment. Homa IR and Homa β were decreased from 1.54±0.34 to 0.83±0.38 and from 5.83±0.55 to 4.95±0.54 (P<0.05) in the rosiglitazone group. The body mass index(BMI) was decreased from 25.30±3.64 to 23.83±2.32 in the metformon group (P<0.05). There were no significant changes in ovulation rate and pregnancy rate between groups (P>0.05). Conclusion Rosiglitazone can increase insulin sensitivity. Metformon may reduce BMI. They all restore regular menstrual cycles, increase pregnancy rate, and reduce testosterone and LH concentration in women with polycystic ovary syndrome.

Objective To construct the plasmid pSilencer4.1/HtrA1 and stably transfect human trophoblastic cell line HPT-8.Methods We detected the expression of HtrA1 in cell line HPT-8 with immunohistochemical SABC,constructed the plasmid pSilencer4.1/HtrA1,transfected human trophoblastic cell line HPT-8 with plasmid pSilencer4.1/HtrA1 and negative plasmid pSilencer4.1, and observed the cell expression after transfection. Results About 90% of cellular cytoplasm of HPT-8 was dyed brown while the nucleus was negatively stained. Selective concentration of G418 was 200 μg/mL for HPT-8 to be transfected pSilencer4.1/HtrA1.With RT-PCR and Western blot methods,the expression of HPT-8 transfected plasmid Psilence4.1/HtrA1 was significantly downregulated compared with that of cells with negative plasmid and normal cells (P < 0.05 ).There was no significant difference in absorbance value between blank plasmid group and HPT-8 group (P >0.05).Conclusion We successfully constructed stable trophoblastic cell line HPT-8/ pSilencer4.1-HtrA1 with silenced expression of HtrA1,which lays foundation for further research.

The postnatal development of the ectoplasmic specialization (ES) of Sertoli cells was investigated in the rats from 1st to 8th week after birth and the adult by electron microscopy. At the end of the 1st week. ES is in the beginning of its formation. Some high electron dense materials accumulate in the submembranous regions and short cisternae of endoplasmic reticulum align in these zones. At the end of the 2nd week the short cisternae are fused each other and straight microfilaments bundles appear and are sandwiched between the flattened cisternae and cell membrane. The density of microfilaments is increased in the 3th week and numerous tight junctions appear between adjacent Sertoli cells. The ES is gradually completed in its structure until the 5th week and fully extend and circumscribed around the base of Sertoli cells. Thereafter, there is no more morphological changes. We conclude that the first 5 weeks after birth is the important period for the development of ES of Sertoli cell as well as the blood-testis barrier in rats.

ObjectiveTo review the surgical technique and outcome of intracranial angiographically occult vascular malformations (AOVM) hemorrhage. Methods40 patients with spontaneous intracranial hemorrhage episodes and accepted microsurgery were analyzed retrospectively. ResultsAll AOVMs were successfully resected. No operative death occurred.36 patients were followed up for mean 28 months. CT and/or MRI revealed no residual lesions. Most neurological complications improved postoperatively. 1 case demonstrated rebleeding in surgical site 48 months after operation. Another case, a follow-up MRI scan revealed a contralateral denovo lesion 44 months after operation.ConclusionA current neurosurgical procedure is a satisfactory method to prevents AOVMs rebleeding. Long-term follow-up evaluation is necessary despite the lesion has been totally resected.

Professor LU Zhi-zheng, one of the first traditional Chinese medicine masters, is good at using tenuifoliain clinical practice, which often brings unexpected surprises. Lu said, tenuifolia is a mild herbal medicine with the nature of upward dispersion and outward penetration but not dryness. Tenuifolia has the following functions: making people conscious, relieving sore throat, diverging incubated diseases, regulating functional activities of qi, sending up Yang, dispelling wind evil and eliminating dampness, and activating collaterals to relieve pain. When well used, it will not only enhance the effect of monarch drug, but also restrict the impetuosity nature in a prescription, achieving better efficacy.
Adult ; Brassicaceae ; chemistry ; Dizziness ; drug therapy ; Drugs, Chinese Herbal ; administration & dosage ; Female ; Humans ; Male ; Phytotherapy ; Rhinitis, Allergic ; drug therapy ; Stomach Diseases ; drug therapy

BACKGROUND: Contingent negative variation (CNV) is a kind of cerebral evoked potential, which is closely related with mental medicine and psychology.OBJECTIVE: To investigate the different manifestations between patients with affective disorder and normal adults in CNV detection.DESIGN: Case-control trial.SETTING: Department of Function, Psychiatric Hospital of Zibo, Shandong Province.PARTICIPANTS: Totally 29 inpatients and outpatients including 14 males and 15 females with affective disorder in the Fifth People's Hospital of Zibo between February 2005 and January 2006 were selected. The guardians were all informed and agreed the content; the diagnosed criteria of the patients were accorded wit h the criteria of DSM-Ⅳ. According to their mental status when hospitalized, the patients were divided into manic episode group and depressive episode group. There were 11 cases in the manic episode group, whose scores of Bech-Rataelson Mania Scale (BRMS)＞16; there were 18 cases in the depressive episode group, including unipolar depression (without history of mania episode) and bipolar depression (with history of mania episode) whose Hamilton Depression Scale (HAMD)scores ＞ 24. A total of 27 healthy hospital staff were selectedas control group including 14 males and 13 females aged 21-53 years and the mean age was (32.5±5.9) years. There was no significant difference in the age and sex among the three groups.METHODS: The CNV test was carried out in a soundproof room. Seating on a soft chair, the subject kept vigilant and focused on a fixed point in the front. The platinum electrode of 8 mm was attached to the subject's vertex Cz according to the International 10/20 System, referred to the right mastoid. The middle point of 2 eyebrows was grounded. The CNV waveforms were described by a L2-3 XY Functional Plotter. Standard CNV was composed of light signal and click signal. The flashlight and loudspeaker were located at the right back of the examinee. The subject was asked to press the button with his right finger to cut off the short sound as soon as his ears received the imperative click. It would take 2 500 ms for one CNV trial, and 20 trials as one experiment. Every subject was given the experiment for twice, and the standard amplitude was set by inputting a standard voltage of 20 μV to the same recording system.MAIN OUTCOME MEASURES: The CNV latency, amplitude B, area of negative expectancy wave before command signal, and area of negative change post-imperative negative variation (PINV) latency of the subjects in the two groups.RESULTS: All the 56 patients were involved in the result analysis.Compared with the control group, the mania group showed higher CNV amplitude [(22.8±4.8) μV; (16.0±5.7) μV; P ＜ 0.01], and the depression group presented smaller A-S2 area [(292.8±161.6)μV2; (412.8±159.9) μV2;P ＜ 0.01], and prolonged PINV latency [(261.9±79.3), (211.9±36.3) ms; P＜ 0.05]. The prolonged PINV latency was found in the unipolar depression group compared with the bipolar depression group [(344.5 ±66.9),(230.4±83.8) ms; P ＜ 0.01].CONCLUSION: CNV and PINV suggest that prolonged latency is the trait maker of the patients with unipolar depression, and CNV amplitude changes belong to the state makers of affective disorder.

Objective To explore the synergistic effectiveness of hyperthermia and chemotherapy in the treatment of advanced gastric cancer.Methods Eighty-nine patients with advanced gastric cancer were randomly assigned to a study group which received a CapeOx chemotherapy regimen supplemented with hyperthermia or to a control group which received only the CapeOx regimen.The regimen consisted of capecitabine (1000 mg/m2,bid,orally for 14 consecutive days) plus oxalipaltin (130 mg/m2) on day 1.The hyperthermia was at 43℃ for 60 min in the tumor area on day 1 and twice a week thereafter.One cycle was 21 days.After 2 treatment cycles,efficacy was evaluated according to RECIST standards,improvements in the quality of life were assessed according to Karnofsky's performance status (KPS) and the side-effects of therapy were recorded.Results The response rate was 68.9％ in the study group and 36.4％ in the control group,showing a significant difference between the groups after two treatment cycles.The median progress-free survival (PFS) was 8.3 months in the study group vs 5.2 months for the controls.The 1-year survival rate was 66.4％ vs 45.5％ and the rate of improvement in KPS was 77.8％ vs 45.5％.All these differences were statistically significant.The common adverse effects were gastrointestinal toxicity,marrow depression and peripheral nerve abnormalities,but these adverse effects were all mild and similar in the two groups.Conclusion Hyperthermia when combined with the CapeOx chemotherapy regimen might improve the therapeutic effect in advanced gastric cancer without obviously increasing the adverse effects.

Monoclonal antibodies(mAbs)to human TRAIL receptors(TRAIL-Rs)have been developed in tumor targeted therapy and currently used in clinical Ⅰ~Ⅳtrials.MAbs can bind death-receptors(TRAIL-R1 and TRAIL-R2)and then results in formation of the death inducing signaling complex (DISC)and apoptosis of tumor cells.TRAIL -Rs mAbs have become one of the research and development hotspots of anti -tumor drugs.These mAbs have achieved remarkable results in combination with radio -or chemo-therapy drugs or oth-er agents and immunotherapy in the treatment of tumor and offer a new therapeutic strategy for clinical tumor treatment.